What's in Sanifit Therapeutics S. A.'s pipeline?

Sanifit Therapeutics S. A. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Sanifit Therapeutics S. A.'s portfolio?

Top competitors by shared drug class: Amgen, Multitude Therapeutics Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sanifit-therapeutics-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sanifit Therapeutics S. A. — Portfolio Competitive Intelligence Brief

Sanifit Therapeutics S. A. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Experimental: SNF472	Experimental: SNF472	phase 3	Calcimimetic agent	Calcium-sensing receptor (CaSR)	Nephrology / Cardiovascular

Therapeutic area mix

Nephrology / Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Multitude Therapeutics Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sanifit Therapeutics S. A.:

Cite this brief

Drug Landscape (2026). Sanifit Therapeutics S. A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sanifit-therapeutics-s-a. Accessed 2026-05-16.